Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review.

[1]  F. Saldanha-Araújo,et al.  Mesenchymal stem cells immunomodulation: The road to IFN-γ licensing and the path ahead. , 2019, Cytokine & growth factor reviews.

[2]  Meng Zhao,et al.  Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review , 2019, World journal of stem cells.

[3]  K. Swiech,et al.  Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization , 2018, Stem cells international.

[4]  T. Kasai-Brunswick,et al.  Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials , 2017, Arquivos brasileiros de cardiologia.

[5]  Robert C. Hendel,et al.  Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study) , 2017, Circulation research.

[6]  A. Caplan.  Mesenchymal Stem Cells: Time to Change the Name! , 2017, Stem cells translational medicine.

[7]  F. Abo‐Aziza,et al.  The Impact of Confluence on Bone Marrow Mesenchymal Stem (BMMSC) Proliferation and Osteogenic Differentiation , 2017, International journal of hematology-oncology and stem cell research.

[8]  E. Masliah,et al.  Pericytes of Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo. , 2017, Cell stem cell.

[9]  H. Koo,et al.  Cell culture density affects the stemness gene expression of adipose tissue-derived mesenchymal stem cells. , 2017, Biomedical reports.

[10]  R. Hendel,et al.  Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. , 2017, Journal of the American College of Cardiology.

[11]  A. Quyyumi,et al.  Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic CardiomyopathyNovelty and Significance , 2017 .

[12]  A. Quyyumi,et al.  Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. , 2016, Circulation research.

[13]  M. Ferrante,et al.  Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial , 2016, The Lancet.

[14]  S. Marsal,et al.  Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial , 2016, Annals of the rheumatic diseases.

[15]  A. Tyndall.  Mesenchymal stromal cells and rheumatic disorders. , 2015, Immunology letters.

[16]  J. García-Sancho,et al.  Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial , 2015, Transplantation.

[17]  L. Shapiro,et al.  The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease. , 2015, Pharmacology & therapeutics.

[18]  A. Heldman,et al.  Rationale and Design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (The POSEIDON-DCM Study) , 2014, Journal of Cardiovascular Translational Research.

[19]  Katherine C. Wu,et al.  Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Sur , 2014, Circulation research.

[20]  S. Cramer,et al.  Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke , 2014, Neurology.

[21]  J. Wagner,et al.  Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  Seok-Goo Cho,et al.  Clinical applications of mesenchymal stem cells , 2013, The Korean journal of internal medicine.

[23]  Ana Sánchez,et al.  Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells: A Pilot Study , 2013, Transplantation.

[24]  L. Sensébé,et al.  Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review , 2013, Stem Cell Research & Therapy.

[25]  M. Sever,et al.  Effects of Intracoronary CD34+ Stem Cell Transplantation in Nonischemic Dilated Cardiomyopathy Patients: 5-Year Follow-Up , 2013, Circulation research.

[26]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[27]  H. Abele,et al.  Phenotypic and functional heterogeneity of human bone marrow– and amnion‐derived MSC subsets , 2012, Annals of the New York Academy of Sciences.

[28]  R. Ramasamy,et al.  Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. , 2012, World journal of stem cells.

[29]  Arnold I Caplan,et al.  The MSC: an injury drugstore. , 2011, Cell stem cell.

[30]  S. Böhm,et al.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC , 2011, Cell Communication and Signaling.

[31]  Peter A. Altman,et al.  Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi , 2011, American heart journal.

[32]  M. Matthay,et al.  Mesenchymal stem cells for acute lung injury: preclinical evidence. , 2010, Critical care medicine.

[33]  P. Eysel,et al.  The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. , 2010, Deutsches Arzteblatt international.

[34]  Hélène Rouard,et al.  Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. , 2010, Blood.

[35]  T. Soukup,et al.  Dental pulp stem cells and their characterization. , 2009, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[36]  F. Farina,et al.  Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers , 2009, Histochemistry and Cell Biology.

[37]  S. Badylak,et al.  A perivascular origin for mesenchymal stem cells in multiple human organs. , 2008, Cell stem cell.

[38]  I. Fischer,et al.  Effects of plating density and culture time on bone marrow stromal cell characteristics. , 2008, Experimental hematology.

[39]  H. Klingemann,et al.  Mesenchymal Stem Cells – Sources and Clinical Applications , 2008, Transfusion Medicine and Hemotherapy.

[40]  A. Caplan.  Adult mesenchymal stem cells for tissue engineering versus regenerative medicine , 2007, Journal of cellular physiology.

[41]  Lindolfo da Silva Meirelles,et al.  Mesenchymal stem cells reside in virtually all post-natal organs and tissues , 2006, Journal of Cell Science.

[42]  Ardeshir Ghavamzadeh,et al.  BMC Cell Biology BioMed Central Research article Aging of mesenchymal stem cell in vitro , 2005 .

[43]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[44]  Arnold I. Caplan,et al.  Mesenchymal Stem Cells , 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[45]  B. Thompson,et al.  Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. , 2015, The Lancet. Respiratory medicine.

[46]  Darcy L. DiFede,et al.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. , 2014, JAMA.